Edoxaban
- Generic Name
- Edoxaban
- Brand Names
- Lixiana, Savaysa, Roteas
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30ClN7O4S
- CAS Number
- 480449-70-5
- Unique Ingredient Identifier
- NDU3J18APO
- Background
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic em...
- Indication
Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the tr...
- Associated Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism
- Associated Therapies
- -
Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Emily McDonald
- Target Recruit Count
- 300
- Registration Number
- NCT06650501
- Locations
- 🇨🇦
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada
The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 324
- Registration Number
- NCT06449469
- Locations
- 🇩🇰
Aarhus University Hospital, Skejby, Aarhus, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Target Recruit Count
- 168
- Registration Number
- NCT06285942
- Locations
- 🇮🇹
Ospedale Policlinico San Martino, Genova, Italy
🇮🇹AOU Maggiore della Carità, Novara, Italy
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2023-11-29
- Target Recruit Count
- 366
- Registration Number
- NCT06149533
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1100
- Registration Number
- NCT05804747
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Galaxia Empírica
- Target Recruit Count
- 456
- Registration Number
- NCT05732506
- Locations
- 🇪🇸
Hospital Universitario de Getafe, Getafe, Madrid, Spain
🇪🇸Hospital Universitario de La Plana, Villa-Real, Castellón, Spain
🇪🇸Hospital Universitario del Vinalopó, Elche, Alicante, Spain
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
- Conditions
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Sung-Hwan Kim
- Target Recruit Count
- 240
- Registration Number
- NCT05540587
- Locations
- 🇰🇷
Bucheon St. Mary's hospital, Bucheon, Korea, Republic of
🇰🇷Yeouido St. Mary's hospital, Yeongdeungpo-gu, Seoul, Korea, Republic of
🇰🇷Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of
Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 120
- Registration Number
- NCT05320627
- Locations
- 🇨🇳
Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
- Target Recruit Count
- 234
- Registration Number
- NCT05262322
- Locations
- 🇬🇧
Royal Victoria Infirmary - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
🇬🇧Queen Elizabeth University Hospital - NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧Gloucestershire Royal Hospital - Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- VarmX B.V.
- Target Recruit Count
- 105
- Registration Number
- NCT05152420
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.